Hello World!
Щедрик, щедрик, щедривочка
Прилетела ласточка
Стала себе щебетать
Хозяина вызывать
- Выйди, выйди, хозяин,
Посмотри на овчарню
Там овечки окотились
COSENTYX is the first FDA-approved biologic of its kind to treat AS by targeting a molecule called IL-17A, one of the molecules that could play a role in inflammation in people with ankylosing spondylitis. A biologic is a protein-based medication that is made from living sources and taken by injection or infusion.
Sign up for a personalized resource that will help you and your doctor make the right
New Fuse. Code. 90890
COSENTYX has a well-studied safety profile. In 2015, COSENTYX was FDA approved to treat adults with moderate to severe plaque psoriasis. In 2016, it was FDA approved to treat active ankylosing spondyl
COSENTYX has a well-studied safety profile. In 2015, COSENTYX was FDA approved to treat adults with moderate to severe plaque psoriasis. In 2016, it was FDA approved to treat active ankylosing spondylitis and active psoriatic arthritis in adults. Then, it was approved in 2020 to treat adults with non-radiographic axial spondyloarthritis. It has since been approved to treat children with plaque psoriasis (6 years and older), psoriatic arthritis (2 years and older), and enthesitis-related arthritis (4 years and older).
2 COSENTYX has a well-studied safety profile. In 2015, COSENTYX was FDA approved to treat adults with moderate to severe plaque psoriasis. In 2016, it was FDA approved to treat a
Fuse. Code65